Drug Overdose Prevention Program Supplement

According to the CDC, Kentucky had the 4th highest age-adjusted drug overdose (DO) fatality rate in the nation, with 24.7 drug overdose fatalities per 100,000 population in 2014, a 4.2% increase over the 2013 rate. The Kentucky (Ky) Injury Prevention and Research Center’s (KIPRC) (a bona fide agent for the Ky Department for Public Health) currently CDC-funded Drug Overdose Prevention Program (KDOPP) uses a three-pronged strategy approach: 1) ENHANCE AND MAXIMIZE KASPER’S (Ky’s prescription drug monitoring program) USE AND EFFECTIVENESS through integration of KASPER with electronic health records; developing/delivering prescriber continuing education training on KASPER; implementing a 100 MME warning flag on KASPER reports; establishing a multi-source drug overdose fatality surveillance system; and conducting nonfatal DO surveillance; 2) IMPLEMENT COMMUNITY INTERVENTIONS by creating a multidisciplinary data-focused DO prevention group; establishing the KIPRC Drug Overdose Technical Assistance Core; enhancing local health department use of DO/abuse data results; and enhancing prevention education on naloxone use by prescribers and law enforcement; and 3) CONDUCT POLICY EVALUATION through cost-benefit analyses of prescribing regulations for schedule II-IV CSs by clinical profession and Ky’s decedent CS testing law. The objective of the KDOPP supplement is to enhance KDOPP’s community interventions through 1) Establishment and implementation of the Ky Substance Use Disorder Information and Referral Service (SUD-IRS) and Treatment Availability Website (SUD-TAW); 2) Integration opioid related syndromic surveillance data with laboratory opioid testing data; 3) Use of overlapping public health, SUD treatment, and other relevant data to identify opioid hot spots and cold spots; and 4) evaluation transition of ICD-9-CM to ICD-10-CM drug overdose/abuse/dependence codes in emergency department and inpatient hospitalization data. Anticipated outcomes of this supplement include increased SUD treatment (ultimately a decrease); decreased rates of opioid abuse; decreased rate of ED visits and IHs due to SUD; decreased age-adjusted opioid overdose mortality rate; improved health outcomes in high opioid-dependent counties; increased patient standard of care for SUD patients; improved state and county SUD prevention policies; and evidence-based community SUD prevention interventions.